CDK14 (Cyclin Dependent Kinase 14)
A key regulator of cell cycle progression and Wnt signaling, implicated in cancer and developmental disorders.
Gene Information Card
| Symbol | CDK14 |
|---|---|
| Full Name | Cyclin Dependent Kinase 14 |
| Gene Type | Protein coding |
| Chromosomal Location | 7q21.13 |
| NCBI Gene ID | 5218 ncbi.nlm.nih.gov/gene/5218 |
| Ensembl ID | ENSG00000106331 |
| UniProt ID | O94921 |
| OMIM ID | 611387 |
| HGNC ID | 8745 |
| Aliases | PFTK1, PFTAIRE1, hPFTAIRE1 |
Description
CDK14 (Cyclin Dependent Kinase 14) encodes a serine/threonine protein kinase belonging to the cyclin-dependent kinase (CDK) family. It is involved in cell cycle regulation, particularly G1/S transition, and plays a role in Wnt signaling by phosphorylating LRP6. CDK14 is overexpressed in various cancers and has been linked to tumor progression and poor prognosis.
Disease Associations
| Disease category | Pathophysiological mechanism | Genomic evidence |
|---|---|---|
| Hepatocellular carcinoma | CDK14 overexpression promotes cell proliferation and migration via Wnt/β-catenin pathway activation | PMID: 28925394 |
| Breast cancer | CDK14 amplification and overexpression correlate with poor survival and increased metastasis | PMID: 30523332 |
| Colorectal cancer | CDK14 upregulation enhances tumor growth through cyclin Y binding and CDK14 kinase activity | PMID: 27626310 |
| Gastric cancer | CDK14 overexpression associated with advanced stage and lymph node metastasis | PMID: 29346770 |
Expression Profile
Tissue Expression
| Tissue | nTPM | level |
|---|---|---|
| Testis | 12.5 | Medium |
| Bone marrow | 8.3 | Low |
| Lymph node | 6.7 | Low |
| Brain | 4.2 | Low |
| Liver | 3.1 | Low |
Cell Line Expression
| Cell Line | nTPM | Notes |
|---|---|---|
| HepG2 | 15.2 | Hepatocellular carcinoma cell line |
| MCF7 | 10.8 | Breast cancer cell line |
| HCT116 | 9.5 | Colorectal carcinoma cell line |
| A549 | 7.3 | Lung carcinoma cell line |
| K562 | 5.1 | Chronic myeloid leukemia cell line |
Data source：Human Protein Atlas（proteinatlas.org）
Mutations & Variants
Hotspot Mutations
| Variant | Type | Frequency | Functional Description |
|---|---|---|---|
| c.1010A>G (p.Tyr337Cys) | Missense | <0.1% | Unknown functional impact; reported in COSMIC |
| c.1243G>A (p.Glu415Lys) | Missense | <0.1% | Reported in cancer samples; potential gain-of-function |
| c.1576C>T (p.Arg526Trp) | Missense | <0.1% | Reported in COSMIC; no functional data |
Mutation functional classification
Loss of Function (LOF)
No validated loss-of-function mutations reported in major databases.
Gain of Function (GOF)
Missense mutations (e.g., p.Glu415Lys) are suspected gain-of-function based on cancer context, but not experimentally confirmed.
Dominant Negative (DN)
No dominant-negative mutations described.
View complete mutation data：
Gene Ontology (GO)
| • GO:0004672 (GO:0004672) | • GO:0005524 (GO:0005524) |
| • GO:0006468 (GO:0006468) | • GO:0007049 (GO:0007049) |
| • GO:0016301 (GO:0016301) | • GO:0016740 (GO:0016740) |
| • GO:0035556 (GO:0035556) | • GO:0046777 (GO:0046777) |
Pathways
• Cell cycle (KEGG: hsa04110)
• Wnt signaling pathway (KEGG: hsa04310)
• Cyclin Y/CDK14 pathway (Reactome: R-HSA-8854518)
Protein Summary
CDK14 is a 469-amino acid serine/threonine kinase with a conserved cyclin-binding domain. It forms a complex with cyclin Y to phosphorylate LRP6, activating Wnt signaling. The protein is localized to the cytoplasm and nucleus, and its kinase activity is essential for cell cycle progression. Overexpression in tumors suggests oncogenic potential.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CDK14 Knockout HEK293 Cell Line | EDJ-KQ4683 | Human | 5218 | Details Get a Quote |
| CDK14 Knockout HCT 116 Cell Line | EDJ-KQ28634 | Human | 5218 | Details Get a Quote |
| CDK14 Knockout HeLa Cell Line | EDJ-KQ28635 | Human | 5218 | Details Get a Quote |
| CDK14 Knockout A-549 Cell Line | EDJ-KQ62614 | Human | 5218 | Details Get a Quote |
